Back
Akamai Technologies 10K Form
Sell
35
AKAM
Akamai Technologies
Last Price:
$80.47
Seasonality Move:
5.67%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2025-03-15 | 10K | AKAM/Akamai Technologies Annual |
2025-02-15 | 10K | AKAM/Akamai Technologies Annual |
2024-11-08 | 10Q | AKAM/Akamai Technologies Quarterly |
2024-08-08 | 10Q | AKAM/Akamai Technologies Quarterly |
2024-05-09 | 10Q | AKAM/Akamai Technologies Quarterly |
2024-02-28 | 10K | AKAM/Akamai Technologies Annual |
Receive AKAM News And Ratings
See the #1 stock for the next 7 days that we like better than AKAM
AKAM Financial Statistics
Sales & Book Value
Annual Sales: | $4B |
---|---|
Cash Flow: | $180.9M |
Price / Cash Flow: | 14.82 |
Annual Sales: | $32.52 |
Price / Book: | 2.47 |
Profitability
EPS (TTM): | 3.26000 |
---|---|
Net Income (TTM): | $504.9M |
Gross Margin: | $2.4B |
Return on Equity: | 10.67% |
Return on Assets: | 5% |
Akamai Technologies Earnings Forecast
Key Akamai Technologies Financial Ratios
-
The Gross Profit Margin over the past 27 years for AKAM is 59.39%.
-
The Selling, General & Administrative Expenses for AKAM have been equal to 27.58% of Gross Profit Margin.
-
The Research & Development expenses have been 11.80% of Revenue.
-
The Interest Expense is 5.37% of Operating Income.
-
The Net Earning history of AKAM is 12.65% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 17 years.
Akamai Technologies Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | IT Services |
Sector: | Information Technology |
Current Symbol: | AKAM |
CUSIP: | 00971T |
Website: | akamai.com |
Debt
Debt-to-Equity Ratio: | 0.73 |
---|---|
Current Ratio: | 1.23 |
Quick Ratio: | 1.11 |
Price-to-Earnings
Trailing P/E Ratio: | 24.48 |
---|---|
Forward P/E Ratio: | 11.89 |
AKAM Technical Analysis vs Fundamental Analysis
Sell
35
Akamai Technologies (AKAM)
is a Sell
Is Akamai Technologies a Buy or a Sell?
-
Akamai Technologies stock is rated a SellThe current Akamai Technologies [AKAM] share price is $80.05. The Score for AKAM is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.